Table 1 |
|||||
|
Comparison of statin effects on murine collagen-induced arthritis |
|||||
|
Study |
Statin |
Dose (mg/kg) |
Exposure route |
Timing (days) |
Effect on arthritis |
|
|
|||||
|
Present study |
A |
10 |
Oral |
-28 to 20 |
ΔET50 -7 days |
|
Present study |
A |
10 |
Oral |
22 to 42 |
ΔET50 -9 days |
|
Present study |
P |
40 |
Oral |
-28 to 20 |
ΔET50 -5 days |
|
Present study |
P |
40 |
Oral |
22 to 42 |
ΔET50 -7 days |
|
Ho and colleagues [13] |
A |
10 |
Oral |
2 to 49 |
Suppression |
|
Yamagata and colleagues [14] |
P |
100 |
Intraperitoneal |
0 to 35 |
Suppression |
|
Leung and colleagues [15] |
S |
40 |
Intraperitoneal |
21 to 40 |
Suppression |
|
Leung and colleagues [15] |
S |
20 |
Intraperitoneal |
21 to 40 |
No effect |
|
Leung and colleagues [15] |
S |
10 |
Intraperitoneal |
21 to 40 |
No effect |
|
Palmer and colleagues [16] |
A |
100 |
Oral |
0 to 48 |
No effect |
|
Palmer and colleagues [16] |
A |
1 |
Oral |
0 to 48 |
No effect |
|
Palmer and colleagues [16] |
R |
2 |
Subcutaneous |
0 to 48 |
No effect |
|
Palmer and colleagues [16] |
R |
0.2 |
Subcutaneous |
0 to 48 |
No effect |
|
Palmer and colleagues [16] |
R |
40 |
Intraperitoneal |
21 to 35 |
No effect |
|
Palmer and colleagues [16] |
S |
40 |
Intraperitoneal |
21 to 35 |
Suppression |
|
Palmer and colleagues [16] |
S |
40 |
Oral |
21 to 35 |
No effect |
|
|
|||||
|
A, atorvastatin; P, pravastatin; S, simvastatin; R, rosuvastatin; ΔET50, number of days between the time when 50% of the animals developed arthritis (ET50 value) for the statin-treated animals and the ET50 value for the control animals. |
|||||
|
Vandebriel et al. Arthritis Research & Therapy 2012 14:R90 doi:10.1186/ar3814 |
|||||